Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast

BMC Genomics

Volumn 12, Issue , 2011, Pages

  Gatti, Laura ^a   Hoe, Kwang L ^b   Hayles, Jacqueline ^c   Righetti, Sabina C ^a   Carenini, Nives ^a   Bo, Laura D ^a   Kim, Dong U ^b   Park, Han O ^d   Perego, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d Bioneer Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEASOME; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME 13; PMT3 PROTEIN, S POMBE; REPRESSOR PROTEIN; SCHIZOSACCHAROMYCES POMBE PROTEIN; UBC13 PROTEIN, S POMBE; UBIQUITIN CONJUGATING ENZYME;

ARTICLE; BETA7 20S GENE; CONTROLLED STUDY; DELETION MUTANT; DNA DAMAGE; DRUG RESISTANCE; DRUG SENSITIVITY; FUNGAL STRAIN; GENE; GENE CONSTRUCT; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; HOMOLOGOUS RECOMBINATION; LET1 GENE; LUB1 GENE; NONHUMAN; PMT13 GENE; RPT6 GENE; SCHIZOSACCHAROMYCES POMBE; UBC13 GENE; UBP16 GENE; UFD2 GENE; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; SCHIZOSACCHAROMYCES;

EUKARYOTA; SCHIZOSACCHAROMYCES POMBE; SCHIZOSACCHAROMYCETACEAE;

CISPLATIN; PROTEASOME ENDOPEPTIDASE COMPLEX; REPRESSOR PROTEINS; SCHIZOSACCHAROMYCES; SCHIZOSACCHAROMYCES POMBE PROTEINS; UBIQUITIN; UBIQUITIN-CONJUGATING ENZYMES;

EID: 78651491709     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-12-44     Document Type: Article

References (53)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584. 10.1038/nrc2167, 17625587.
2. Cossa G, Gatti L, Zunino F, Perego P. Strategies to improve the efficacy of platinum compounds. Curr Med Chem 2009, 16:2355-2365. 10.2174/092986709788682083, 19601785.
3. Gatti L, Chen D, Beretta GL, Rustici G, Carenini N, Corna E, Colangelo D, Zunino F, Bähler J, Perego P. Global gene expression of fission yeast in response to cisplatin. Cell Mol Life Sci 2004, 61:2253-2263.
4. Perego P, Jimenez GS, Gatti L, Howell SB, Zunino F. Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev 2000, 52:477-492.
5. Pickart CM. Back to the future with ubiquitin. Cell 2004, 116:181-190. 10.1016/S0092-8674(03)01074-2, 14744430.
6. Motegi A, Murakawa Y, Takeda S. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. Cancer Letters 2009, 283:1-9. 10.1016/j.canlet.2008.12.030, 19201084.
7. Kodadek T, Sikder D, Nalley K. Keeping transcriptional activators under control. Cell 2006, 127:261-264. 10.1016/j.cell.2006.10.002, 17055428.
8. Kim D-U, Hayles J, Kim D, Wood V, Park H-O, Won M, Yoo H-S, Duhig T, Nam M, Palmer G, Han S, Jeffrey L, Baek S-T, Lee H, Shim YS, Lee M, Kim L, Heo K-S, Noh EJ, Lee A-R, Jang Y-J, Chung K-S, Choi S-J, Park J-Y, Park Y, Kim HM, Park S-K, Park H-J, Kang E-J, Kim HB, Kang H-S, Park H-M, Kim K, Song K, Song KB, Nurse P, Hoe K-L. Analysis of a genome-wide set of gene deletions in the fission yeast Schizosaccharomyces pombe. Nature Biotechnol 2010, 28:617-623.
9. Aslett M, Wood V. Gene ontology annotation status of the fission yeast genome:preliminary coverage approaches 100%. Yeast 2006, 23:913-919. 10.1002/yea.1420, 17072883.
10. The Gene Ontology Consortium The Gene Ontology in 2010: extensions and refinements. Nucl Acids Res 2010, 38:D331-D335. 10.1093/nar/gkp1018, 2808930, 19920128, The Gene Ontology Consortium.
11. Calzari L, Orlandi I, Alberghini L, Vai M. The histone deubiquitinating enzyme Ubp10 is involved in rDNA locus control in Saccharomyces cerevisiae by affecting Sir2p association. Genetics 2006, 174:2249-2254. 10.1534/genetics.106.063099, 1698635, 17028327.
12. Lis ET, Romesberg FE. Role of Doa1 in the Saccharomyces cerevisiae DNA damage response. Mol Cell Biol 2006, 26:4122-4133. 10.1128/MCB.01640-05, 1489103, 16705165.
13. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science 2003, 301:798-802. 10.1126/science.1086887, 12907790.
14. Orlandi I, Bettiga M, Alberghina L, Vai M. Transcriptional profiling of ubp10 null mutant reveals altered subtelomeric gene expression and insurgence of oxidative stress response. J Biol Chem 2004, 279:6414-6425. 10.1074/jbc.M306464200, 14623890.
15. Bettiga M, Calzari L, Orlandi I, Alberghina L, Vai M. Involvement of the yeast metacaspase Yca1 in ubp10Delta-programmed cell death. FEMS Yeast Res 2004, 5:141-147. 10.1016/j.femsyr.2004.07.005, 15489197.
16. Glinsky GV. Genomic models of metastatic cancer. Cell Cycle 2006, 5:1208-1216. 10.4161/cc.5.11.2796, 16760651.
17. Lee H-J, Kim M-S, Shin J-M, Park T-J, Chung H-M, Baek K-H. The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expression Patterns 2006, 6:277-284. 10.1016/j.modgep.2005.07.007, 16378762.
18. Ovaa H, Kessler BM, Rolen U, Galardy PJ, Ploegh HL, Masucci MG. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA 2004, 101:2253-2258. 10.1073/pnas.0308411100, 356937, 14982996.
19. Rolen U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F, Masucci MG. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog 2006, 45:260-269. 10.1002/mc.20177, 16402389.
20. Brown M, Zhu Y, Hemmingsen SM, Xiao W. Structural and functional conservation of error-free DNA postreplication repair in Schizosaccharomyces pombe. DNA Repair 2002, 1:869-880. 10.1016/S1568-7864(02)00111-8, 12531016.
21. Frampton J, Irmisch A, Green CM, Neiss A, Trickey M, Ulrich HD, Furuya K, Watts FZ, Carr AM, Lehmann AR. Postreplication repair and PCNA modification in Schizosaccharomyces pombe. Mol Biol Cell 2006, 17:2976-2985. 10.1091/mbc.E05-11-1008, 1483034, 16641370.
22. Broomfield S, Chow BL, Xiao W. MMS2, encoding a ubiquitin-conjugating-enzyme-like protein, is a member of the yeast error-free postreplication repair pathway. Proc Natl Acad Sci USA 1998, 95:5678-5683. 10.1073/pnas.95.10.5678, 20438, 9576943.
23. Brusky J, Zhu Y, Xiao W. UBC13, a DNA-damage-inducible gene is a member of the error-free postreplication repair pathway in Saccharomyces cerevisiae. Curr Genet 2000, 37:168-174. 10.1007/s002940050515, 10794173.
24. Andersen PL, Zhou H, Pasthshok L, Moraes T, McKenna S, Ziola B, Ellison MJ, Dixit VM, Xiao W. Distinct regulation of Ubc13 functions by the two ubiquitin-conjugating enzyme variants Mms2 and Uev1A. J Cell Biol 2005, 170:745-755. 10.1083/jcb.200502113, 2171356, 16129784.
25. Pastushok L, Spyracopoulos L, Xiao W. Two Mms2 residues cooperatively interact with ubiquitin and are critical for Lys63 polyubiquitination in vitro and in vivo. FEBS Lett 2007, 581:5343-5348.
26. Tanaka K, Nishide J, Okazaki K, Kato H, Niwa O, Nakagawa T, Matsuda H, Kawamukai M, Murakami Y. Characterization of a fission yeast SUMO-1 homologue, Pmt3p, required for multiple nuclear events, including the control of telomere length and chromosome segregation. Mol Cell Biol 1999, 19:8660-8672. 85006, 10567589.
27. Skilton A, Ho JCY, Mercer B, Outwin E, Watts FZ. SUMO chain formation is required for response to replication arrest in S. pombe. Plos One 2009, 4:e6750. 10.1371/journal.pone.0006750, 2727700, 19707600.
28. Huang R-Y, Kowalski D, Minderman H, Gandhi N, Johnson ES. Small Ubiquitin-related Modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae. Cancer Res 2007, 67:765-772. 10.1158/0008-5472.CAN-06-2839, 17234788.
29. Ghislain M, Dohmen RJ, Levy F, Varshavsky A. Cdc48p interacts with Ufd3p, a WD repeat protein required for ubiquitin-mediated proteolysis in Saccharomyces cerevisiae. Embo J 1996, 15:4884-4899. 452226, 8890162.
30. Keogl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999, 96:635-644. 10.1016/S0092-8674(00)80574-7, 10089879.
31. Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005, 120:73-84. 10.1016/j.cell.2004.11.013, 15652483.
32. Hosoda M, Ozaki T, Miyazaka K, Hayashi S, Furuya K, Watanabe K, Nakagawa T, Hanamoto T, Todo S, Nakagawara A. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 2005, 24:7156-7169. 10.1038/sj.onc.1208872, 16170377.
33. Chatterjee A, Upashyay S, Chang X, Nagpal JK, Trink B, Sidransky D. U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of Δ Np63α. Cell Cycle 2008, 7:1231-1237. 10.4161/cc.7.9.5795, 18418053.
34. Loscher M, Fortschegger K, Ritter G, Wostry M, Voglauer R, Schmid JA, Watters S, Rivett AJ, Ajuh P, Lamond AI, Katinger H, Grillari J. Interaction of U-box E3 ligase SNEV with PSMB4, the β7 subunit of the 20S proteasome. Biochem J 2005, 388:593-603. 10.1042/BJ20041517, 1138967, 15660529.
35. Mahajan KN, Mitchell BS. Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. PNAS 2003, 100:10746-10751. 10.1073/pnas.1631060100, 196874, 12960389.
36. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, Lazo JS. Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 2009, 76:1246-1255. 10.1124/mol.109.058024, 2784725, 19783622.
37. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, Hamalainen K, Schouten JP, Verheijen RH, van Diest PJ, Albertson DG, Dorsman JC. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent proble amplification. J Pathol 2007, 213:46-55. 10.1002/path.2217, 17668415.
38. Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 2007, 38:639-644. 10.1016/j.humpath.2006.07.019, 17367606.
39. Valdagni R, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S, Zaffaroni N, Pierotti MA, Gariboldi M. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiation Oncology Biol Phys 2009, 74:1431-1440.
40. Munkacsy G, Abdul-Ghani R, Mihaly Z, Tegze B, Tchernitsa O, Surowiak P, Schafer R, Gyorffy B. PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. Br J Cancer 2010, 102:361-368. 10.1038/sj.bjc.6605478, 2816652, 20010949.
41. Kim YC, Wu SY, Lim HS, Chiang CM, Kodadek T. Non-proteolytic regulation of p53-mediated transcription through destabilization of the activator promoter complex by the proteasomal ATPases. J Biol Chem 2009, 284:34522-34530. 10.1074/jbc.M109.017277, 2787313, 19846554.
42. Hanway D, Chin JK, Xia G, Oshiro G, Winzeler EA, Romesberg FE. Previously uncharacterized genes in the UV- and MMS-induced DNA damage response in yeast. Proc Natl Acad Sci USA 2002, 99:10605-10610. 10.1073/pnas.152264899, 124988, 12149442.
43. Huang R-Y, Eddy M, Vujcic M, Kowalski D. Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae. Cancer Res 2005, 65:5890-5897. 10.1158/0008-5472.CAN-04-4093, 15994967.
44. Qiu L, Pashkova N, Walker JR, Winistorfer S, Allali-Hassani A, Akutsu M, Piper R, Dhe-Paganon S. Structure and function of the PLAA/Ufd3-p97/Cdc48 complex. J Biol Chem 2010, 285:365-372. 10.1074/jbc.M109.044685, 2804184, 19887378.
45. Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW, Chopra AK. Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cellular Signalling 2009, 21:1085-1099. 10.1016/j.cellsig.2009.02.018, 19258036.
46. Peters DG, Kudla DM, Deloia JA, Chu TJ, Fairfull L, Edwards RP, Ferrell RE. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol Biomarkers Prev 2005, 14:1717-1723. 10.1158/1055-9965.EPI-04-0704, 16030107.
47. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W, Matthias P, Muller CW, Khochbin S. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 2006, 25:3357-3366. 10.1038/sj.emboj.7601210, 1523186, 16810319.
48. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, Garrido C, Yao TP, Vourc'h C, Matthias P, Khochbin S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007, 21:2172-2181. 10.1101/gad.436407, 1950856, 17785525.
49. Kling J. New twists on proteasome inhibitors. Nature Biotechnology 2010, 28:1236-1238. 10.1038/nbt.1727, 21139600.
50. Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans 2009, 37:605-613. 10.1042/BST0370605, 19442257.
51. Espinosa JM. Histone H2B ubiquitination: the cancer connection. Genes Dev 2008, 22:2743-2749. 10.1101/gad.1732108, 2751279, 18923072.
52. Deshpande GP, Hayles J, Hoe K-L, Kim D-U, Park H-O, Hartsuiker E. Screening a genome wide S. pombe deletion library identifies novel genes and pathways involved in the DNA damage response. DNA Repair 2009, 8:672-679. 10.1016/j.dnarep.2009.01.016, 2675035, 19264558.
53. Perego P, Vande Weghe J, Ow DW, Howell SB. Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatin. Mol Pharmacol 1997, 51:12-18.